You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 20, 2024

Claims for Patent: 4,585,790

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,585,790

Title:	Pharmaceutical compositions
Abstract:	Aqueous formulations of raniditine have been found to have enhanced shelf life provided that they are formulated with a pH in the range 6.5--7.5. Suitable aqueous formulations include injections for intravenous and intramuscular administration, continuous infusions and oral preparations such as syrups.
Inventor(s):	Padfield; John M. (Meldreth, GB2), Winterborn; Ian K. (Stevenage, GB2)
Assignee:	Glaxo Group Limited (London, GB2)
Application Number:	06/609,215
Patent Claims:	1. A pharmaceutical composition which is an aqueous formulation containing an effective amount of ranitidine and/or one or more physiologically acceptable salts thereof for treatment of conditions mediated through histamine H.sub.2 -receptors, said formulation having a pH within the range of 6.5-7.5. 2. A pharmaceutical composition according to claim 1 having a pH in the range 6.7 to 7.3. 3. A pharmaceutical composition according to claim 1 having a pH in the range 6.8 to 7.1. 4. A pharmaceutical composition according to claim 1 in which said pH is adjusted by means of suitable buffer salts. 5. A pharmaceutical composition according to claim 4 in which said buffer salts are potassium dihydrogen orthophosphate and disodium hydrogen orthophosphate or citric acid and disodium hydrogen orthophosphate. 6. A pharmaceutical composition according to claim 1 in a form suitable for parenteral administration. 7. A pharmaceutical composition according to claim 6 in a form suitable for injection and containing 10 to 100 mg/ml ranitidine, expressed as free base. 8. A pharmaceutical composition according to claim 6 in a form suitable for continuous infusion and containing 0.1-2.0 mg/ml raniditine, expressed as free base. 9. A pharmaceutical composition according to claim 1 in a form suitable for oral administration. 10. A pharmaceutical composition according to claim 9 containing 20-400 mg per 10 ml dose. 11. A pharmaceutical composition according to claim 1 containing ranitidine in the form of its hydrochloride salt. 12. A process for the production of a composition of claim 1 suitable for parenteral administration, which comprises dissolving ranitidine and/or one or more physiologically acceptable salts thereof and said remaining constituents in water suitable for injection, followed by sterilisation. 13. A process for the production of a composition of claim 1 suitable for oral administration which comprises adding an aqueous solution of ranitidine and/or one or more physiologically acceptable salts thereof to an aqueous solution or dispersion of a viscosity enhancing agent.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.